Pandemic-Related Decreases in Cancer Detection Persist for Some Cancers
The largest declines in incidence were seen for cervical, endocrine, and prostate cancers, as well as melanoma.
All articles by Leah Lawrence
Blood-Based Test May Establish a ‘New Paradigm’ for Cancer Screening
The test can accurately detect cancer and predict where it is located, according to researchers.
Stopping Ipi/Nivo for irAEs Did Not Affect Advanced Melanoma Survival
Immune-related adverse events were associated with improved survival outcomes.
Blood Cell Score for Identifying Aggressive Melanoma
A team of investigators created the myeloid index score, which captures the prognostic value of blood myeloid cells and may be used in the management of patients with melanoma.
Nomogram Developed to Guide Management of Thin Melanomas
Using readily available clinicopathologic information, a team of investigators developed a risk calculator to predict disease recurrence in patients with thin melanomas.
Risk of Melanoma Measured in Mutation Burden of Skin Cells
Mutation count could offer personal screening guidelines.
Skin Toxicity Program Can Positively Address EGFR Inhibitor-Related Skin Toxicities
Patients given prophylactic treatment were 94% less likely to require a first rescue treatment for rash and 74% less likely to require a second rescue treatment.
Model Could Help Identify Who May Respond to Checkpoint Inhibition in Melanoma
Imaging radiomics and blood markers could differentiate pseudoprogression.
Minority of Melanomas With Complete Response to Anti–PD-1 Relapsed After Drug Cessation
More research is needed to define criteria for stopping therapy.
Advanced Melanoma May Benefit From Encorafenib, Binimetinib Combination
The FDA accepted a New Drug Application to support the combination of the MEK inhibitor, binimetinib, and the BRAF inhibitor, encorafenib, for treating patients with BRAF-mutated unresectable or metastatic melanoma.
- Loading...
Loading...
Next post in Skin Cancer
Loading... 
Loading...